For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy. “There are no available data from randomized controlled trials in PsA assessing clinical outcomes in patients who have directly switched from [TNF inhibitors] to tofacitinib, and
Insights into the latest clinical and research studies in orthopaedics. A podcast from JBJS, featuring Antonia Chen, MD, and Andrew Schoenfeld, MD
Created in 2018, the JHS Journal Club is an online journal club that allows you to interact with other Journal of Hand Surgery readers from…
ntersection of mental and physical health among candidates for lumbar fusion has increased. Although there is strong evidence to suggest mental disorders can influence a…
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according…
More men with limited life expectancy and certain localized prostate cancers have received definitive treatment over the past 2 decades despite shifts toward active surveillance,…
Click on the article title to read more.
Nicotine vaping cessation rates were elevated with use of a text message intervention or varenicline vs. no/minimal support or placebo, according to data published in…
Dr Darrell Menard is a distinguished leader in Canadian sport and exercise medicine, renowned for his exceptional contributions on national and international stages. He has…
Find out what happens during a rheumatoid arthritis flare, how it affects daily life, and patient-approved tips to manage symptoms.
Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology. “Cardiovascular…
